SCHEMBL1616018

SCHEMBL1616018

CC1(C)CCC(C)(C)c2cc(/C=C/c3ccc(C(=O)O)cc3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 13/20 1.00
RARG P13631 13/20 1.00
RARA P10276 10/20 1.00
RXRA P19793 12/20 0.72
CYP26A1 O43174 3/20 0.68
CYP3A4 P08684 2/20 0.68
KDM4E B2RXH2 1/20 0.68
NPC1 O15118 1/20 0.68
GMNN O75496 1/20 0.68
USP2 O75604 1/20 0.68
ALDH1A1 P00352 1/20 0.68
LMNA P02545 1/20 0.68
TP53 P04637 1/20 0.68
CYP1A2 P05177 1/20 0.68
POLB P06746 1/20 0.68
CYP2D6 P10635 1/20 0.68
NFKB1 P19838 1/20 0.68
CYP2C19 P33261 1/20 0.68
THPO P40225 1/20 0.68
MTOR P42345 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615597 1.00 RARB (1.00) RARBRARGRARARXRACYP26A1
SCHEMBL1615595 1.00 RARB (1.00) RARBRARGRARARXRACYP26A1
SCHEMBL9747847 0.89 RARB (0.80) RARBRARGRARARXRACYP26A1
4-Aminophenol SCHEMBL10842256 0.89 RARB (0.79) RARBRARGRARARXRACYP26A1
4-Aminophenol SCHEMBL10842270 0.89 RARB (0.79) RARBRARGRARARXRACYP26A1
SCHEMBL8026153 0.88 RARB (0.78) RARBRARGRARARXRACYP26A1
SCHEMBL4315172 0.86 RARB (0.75) RARBRARGRARARXRACYP26A1
SCHEMBL4315169 0.86 RARB (0.75) RARBRARGRARARXRACYP26A1
SCHEMBL1615307 0.85 RARB (0.74) RARBRARGRARARXRACYP26A1
SCHEMBL1615305 0.85 RARB (0.74) RARBRARGRARARXRACYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115430166-B Process system and method for steam driven heat pump auxiliary bulkhead tower 天津大学 2024-06-21 CN claimed
CN-115430166-A Process system and method for steam-driven heat pump auxiliary partition tower 天津大学 2022-12-06 CN claimed
US-20250289443-A1 Custom Application System for Safe Vehicle Operation Applied Electric Vehicles Ltd (AU) 2025-09-18 US disclosed
CN-223093570-U Stator thread end forming module 福建闽光电机制造有限公司 2025-07-11 CN disclosed
CN-119799671-A Protein mutant and application of biological material thereof in production of L-isoleucine 宁夏伊品生物科技股份有限公司 2025-04-11 CN disclosed
CN-119692916-A Material shipment method, system and terminal equipment 深圳市金合联技术股份有限公司 2025-03-25 CN disclosed
CN-119506345-A Application of alfalfa VIK protein in cultivation of phytophthora root rot resistant plants 中国农业大学 2025-02-25 CN disclosed
US-20240410237-A1 WRENCH ASSEMBLY BUMPER PLATE SYSTEMS PATTERSON-UTI DRILLING COMPANY LLC 2024-12-12 US disclosed
CN-115430166-B Process system and method for steam driven heat pump auxiliary bulkhead tower 天津大学 2024-06-21 CN disclosed
CN-220889611-U Prevent concrete cover board repair with mortar spraying equipment of breakfast 山东高速威海发展有限公司 2024-05-03 CN disclosed
CN-110833429-B Computed tomography imaging method, device, equipment and storage medium 上海联影医疗科技股份有限公司 2024-03-26 CN disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 US disclosed
EP-1692097-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS Exonhit Therapeutics SA (FR) 2006-08-23 EP disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 WO disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 WO disclosed
EP-1541549-A1 Tricyclic hydroxamate and benzaminde derivatives, compositions and methods Exonhit Therapeutics S.A. (FR) 2005-06-15 EP disclosed
WO-1999048529-A1 RETINOID-GLITAZONE COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-30 WO disclosed
EP-0808159-A1 USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1997-11-26 EP disclosed
WO-1996024344-A1 USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1996-08-15 WO disclosed
US-5489611-A ADMINISTERING A RETINOID COMPOUND WARNER-LAMBERT COMPANY (US) 1996-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods HDAC5, HDAC1, HDAC2 RARB 998/4885RARG 904/4885RARA 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.